Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
12 August 2008 - 2:00PM
PR Newswire (US)
VANCOUVER, Aug. 12 /PRNewswire-FirstCall/ -- Angiotech
Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), a global
specialty pharmaceutical and medical device company, today
announced that it has received CE Mark approval to begin marketing
the HemoStream(TM) Chronic Dialysis Catheter in Europe. This CE
Mark approval follows Angiotech's announcement in August 2007 that
it had received clearance from the U.S. Food and Drug Association
(FDA) to begin marketing HemoStream in the United States. In April
of the same year, Angiotech entered into an agreement with Rex
Medical, LP that granted Angiotech an exclusive license to market
and distribute HemoStream worldwide. "This CE Mark approval is
another example of the international acceptance of Angiotech's
technologies. With Rex Medical as our worldwide licensing partner,
we look forward to expanding HemoStream's availability in Europe as
well as in the United States," said Dr. William Hunter, President
and CEO of Angiotech. About the HemoStream Chronic Dialysis
Catheter Incidences of End Stage Renal Disease (ESRD) requiring
dialysis are a rapidly growing challenge in healthcare worldwide.
When kidneys fail, function of the kidneys can be partially
replaced using a process called hemodialysis. This process involves
drawing blood out of the body, filtering it through a large machine
and then returning filtered blood back to the body. Chronic
dialysis catheters, such as HemoStream, are used as long-term
vascular access for hemodialysis. HemoStream may also be used as a
temporary access while more permanent options mature or become
ready for use, such as surgically created AV fistulas. About Rex
Medical, LP Rex Medical, LP, based in Conshohocken, PA, is a
privately held medical device company specializing in developing,
manufacturing and marketing of minimally invasive medical devices
targeted towards the cardiovascular, venous access, endosurgery and
oncology markets. About Angiotech Angiotech Pharmaceuticals, Inc.
is a global specialty pharmaceutical and medical device company
with over 1,500 dedicated employees. Angiotech discovers, develops
and markets innovative treatment solutions for diseases or
complications associated with medical device implants, surgical
interventions and acute injury. To find out more about Angiotech
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit
http://www.angiotech.com/. Note on Forward Looking Statements:
Statements contained in this press release that are not based on
historical fact, including without limitation statements containing
the words "believes," "may," "plans," "will," "estimate,"
"continue," "anticipates," "intends," "expects" and similar
expressions, constitute "forward-looking statements" within the
meaning of the U.S. Private Securities Litigation Reform Act of
1995 and constitute "forward-looking information" within the
meaning of applicable Canadian securities laws. All such statements
are made pursuant to the "safe harbor" provisions of applicable
securities legislation. Forward looking statements may involve, but
are not limited to, comments with respect to our objectives and
priorities for the second half of 2008 and beyond, and our
strategies or future actions, our targets, expectations for our
financial condition and the results of, or outlook for, our
operations, research development and product and drug development.
Such forward looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
events or developments to be materially different from any future
results, events or developments expressed or implied by such
forward-looking statements. Many such risks, uncertainties and
other factors are taken into account as part of our assumptions
underlying these forward-looking statements and include, among
others, the following: general economic and business conditions,
both nationally and in the regions in which we operate; market
demand; technological changes that could impact our existing
products or our ability to develop and commercialize future
products; competition; existing governmental regulations and
changes in, or the failure to comply with, governmental
regulations; adverse results or unexpected delays in pre-clinical
and clinical product development processes; adverse findings
related to the safety and/or efficacy of our products or products
sold by our partners; decisions, and the timing of decisions, made
by health regulatory agencies regarding approval of our technology
and products; the requirement for substantial funding to conduct
research and development, to expand manufacturing and
commercialization activities or consummate acquisitions; and any
other factors that may affect performance. In addition, our
business is subject to certain operating risks that may cause the
actual results expressed or implied by the forward-looking
statements in this press release to differ materially from our
actual results. These operating risks include: our ability to
attract and retain qualified personnel; our ability to successfully
complete preclinical and clinical development of our products;
changes in business strategy or development plans; our failure to
obtain patent protection for discoveries; loss of patent protection
resulting from third party challenges to our patents;
commercialization limitations imposed by patents owned or
controlled by third parties; our ability to obtain rights to
technology from licensors; liability for patent claims and other
claims asserted against us; our ability to obtain and enforce
timely patent and other intellectual property protection for our
technology and products; the ability to enter into, and to
maintain, corporate alliances relating to the development and
commercialization of our technology and products; market acceptance
of our technology and products; our ability to successfully
manufacture, market and sell our products; the continued
availability of capital to finance our activities; our ability to
continue to service our debt obligations; and any other factors
referenced in our annual information form and other filings with
the applicable Canadian securities regulatory authorities or the
Securities and Exchange Commission. Given these uncertainties,
assumptions and risk factors, readers are cautioned not to place
undue reliance on such forward looking statements. Except as
required by law, we disclaim any obligation to update any such
factors or to publicly announce the result of any revisions to any
of the forward looking statements contained in this press release
to reflect future results, events or developments. HemoStream(TM)
is a trademark of Rex Medical, LP, used under license by Angiotech
Pharmaceuticals, Inc. DATASOURCE: Angiotech Pharmaceuticals, Inc.
CONTACT: Sage Baker, Investor Relations and Corporate
Communications, Angiotech Pharmaceuticals, Inc., (604) 221-6933,
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2024 bis Aug 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Aug 2023 bis Aug 2024